2028 年前列腺癌核医学诊断市场报告(按细分市场、地域、动态、最新发展和战略见解)

  • Report Code : TIPRE00009519
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2028

Buy Now

 

前列腺癌核医学诊断市场预计将从 2022 年的 7.2012 亿美元增长到 2028 年的 13.1566 亿美元。预计 2022 年至 2028 年的复合年增长率为 10.6%。

前列腺癌会影响男性的前列腺。前列腺癌是男性皮肤癌之后的常见癌症。导致前列腺癌发病的一些常见决定因素是家族史、高龄和种族。核医学是一种需要放射性物质的成像。它是识别和治疗前列腺癌的一种有用方法,可帮助放射科医生确定癌症的分期。前列腺癌核医学诊断市场

类型、PET 产品、最终用户和地域进行分析。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。前列腺癌核医学诊断市场报告提供了对市场的见解和深入分析,强调了市场趋势、市场动态和全球领先市场参与者的竞争分析等参数。    

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

前列腺癌核医学诊断市场:

Prostate Cancer Nuclear Medicine Diagnostics Market: Strategic Insights

Prostate Cancer Nuclear Medicine Diagnostics Market
  • CAGR
    CAGR (2022 - 2028)
    10.6%
  • Market Size 2022
    US$ 720.12 Million
  • Market Size 2028
    US$ 1,315.66 Million

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Blue Earth Diagnostics Limited
  • ImaginAB
  • Curium
  • Jubilant Radiopharma
  • NCM USA LLC
  • ABX Advanced Biochemical Compounds GmbH
  • Telix Pharmaceuticals Ltd
  • Novartis AG
  • Theragonostics

Regional Overview

Regional And Country Scope
  • 北美(美国、加拿大、墨西哥)
  • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
  • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
  • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
  • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)

Market Segmentation

Segment 1类型(PET 和 SPECT)
    Segment2PET 产品(F-18、C-11 和 Ga68-PSMA)
      Segment3最终用户(医院、诊所和其他)

        前列腺癌核医学诊断市场
        • Prostate Cancer Nuclear Medicine Diagnostics Market
          复合年增长率(2022 - 2028)
          10.6%
        • 2022 年市场规模
          7.2012 亿美元
        • 市场规模 2028 年
          13.1566 亿美元

        市场动态

        增长动力
        • 財政部
        • 財政部
        • 財政部
        未来的趋势
        • 財政部
        • 財政部
        • 財政部
        机会
        • 財政部
        • 財政部
        • 財政部

        关键人物;主力;重要一员

        •  
        • 蓝地球诊断有限公司
        • 想象公司
        • 欢庆放射药物公司
        • NCM-美国有限责任公司
        • ABX 先进生化化合物有限公司
        • Telix 制药有限公司
        • 诺华公司
        • 治疗学

        区域概况

        Prostate Cancer Nuclear Medicine Diagnostics Market
        • 北美
        • 欧洲
        • 亚太
        • 南美洲和中美洲
        • 中东和非洲

        市场细分

        Prostate Cancer Nuclear Medicine Diagnostics Market类型
        • PET 和 SPECT
        Prostate Cancer Nuclear Medicine Diagnostics Market宠物产品
        • F-18
        • C-11
        • Ga68-PSMA
        Prostate Cancer Nuclear Medicine Diagnostics Market最终用户
        • 医院
        • 诊所
        • 其他的
        • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

         

         

        市场洞察

        前列腺癌早期精准诊断需求激增,推动前列腺癌核医学诊断市场发展

        PSA 水平升高会增加患前列腺癌的风险。血液中的 PSA 水平以每毫升纳克 (ng/mL) 为单位进行测量。没有明确的临界点可以确定男性是否患有前列腺癌。在评估男性是否需要进一步检测时,许多医生选择将 PSA 临界值设为 4 ng/mL 或更高,而其他医生可能建议从较低的水平开始,例如 2.5 或 3。因此,检测男性血液中的 PSA 水平可以早期发现前列腺癌。

        直肠指检 (DRE) 是检测前列腺癌的另一种方法。医生在检查过程中用戴手套、涂了润滑剂的手指触摸前列腺。使用经过充分验证的生物标记物进行定期筛查可以更快地检测出局部疾病。此外,区分低度和高度疾病对于避免不必要的活检、严重疾病的治疗不足和惰性疾病的过度治疗至关重要。

        以下是一些启动新产品开发和产品批准的公司示例:

        • 2022年4月,Telix宣布其前列腺癌成像剂Illuccix(制备镓68戈泽托肽的试剂盒),也称为68Ga-PSMA-11注射剂,将在美国上市。
        • 2022年3月,诺华宣布,FDA批准Pluvicto(镥Lu177 vipivotide tetraxetan)(原名177Lu-PSMA-617),用于治疗已扩散至身体其他部位(转移性)的前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌(PSMA阳性mCRPC)的成年患者。
        • 2022年3月,FDA批准了一种补充诊断显像剂Locametz,经镓-68放射性标记后可用于识别PSMA阳性病变。放射性标记后,该显像剂可用于通过正电子发射断层扫描识别mCRPC成人患者的PSMA阳性病变。

        市场参与者对此类产品的开发正在推动前列腺癌核医学诊断市场的发展。

        类型洞察

        根据类型,全球前列腺癌核医学诊断市场分为SPECT和 PET。PET 细分市场在 2021 年占据了最大的市场份额。此外,预计同一细分市场在预测期内将在市场上实现最高的复合年增长率。PET 作为诊断工具的采用正在显着增加,因为它比其他诊断技术具有更高的准确性。诊断的准确性直接影响决策和治疗监测过程。预计在预测期内,对这些诊断程序的需求不断增长将推动前列腺癌核医学诊断市场的增长。

         

        服务洞察

        根据 PET 产品,全球前列腺癌核医学诊断市场细分为 F-18、C-11 和 Ga68-PSMA。F-18 细分市场很可能在 2022 年占据最大的市场份额。然而,Ga68-PSMA 细分市场预计将在预测期内实现市场最高复合年增长率。Ga68-PSMA 是一种非侵入性诊断方法,利用增强的前列腺特异性膜抗原 (PSMA) 表达对前列腺癌进行成像。PSMA 是一种遍布前列腺的跨膜蛋白。PSMA 表达在多种癌症中上调,但前列腺癌的水平最高。此外,PSMA 表达对疾病结果具有预测价值。PET 通过测量 Ga68-PSMA 的三维分布生成半定量图像,从而实现 PSMA 表达的非侵入性测量。

        伙伴关系和合作是全球前列腺癌核医学诊断市场参与者广泛采用的策略。以下列出了一些近期的关键市场发展:

        • 2022 年 4 月,Telix 宣布与 Avanço 和 THP 合作,向葡萄牙和奥地利、捷克共和国和斯洛伐克共和国市场分销 Telix 的前列腺癌研究成像产品。
        • 2022 年 8 月,Telix 发布了 ProstACT 计划下两项辅助研究的详细信息,其中包括与 GenesisCare 合作的一项 II 期研究。
        • 2021 年 2 月,Theragnostics 宣布与埃森大学医院达成一项研究协议,研究 THG-008 对几种癌症的 PET 成像,因为放射性标记的 PARP 抑制剂有可能提高癌症患者的生存率。

        COVID-19 疫情的爆发为前列腺癌核医学诊断市场的参与者带来了一些有利的前景。北美地区的许多人都受到了 COVID 19 的影响。美国是北美地区受疫情影响最严重的国家。这种感染严重影响了该国的老年人口,引发了各种并发症,并导致大量人口死亡。例如,截至 2022 年 5 月 16 日,美国报告了 84,230,829 例 COVID 病例,其中 1,026,670 人死亡。此外,慢性伤口或不愈合伤口多见于老年人,愈合时间较长。因此,需要进行前列腺癌核医学诊断和适当的护理,以预防慢性感染和健康状况。

        此外,由于新冠疫情的爆发,各家医院都在忙于治疗感染者。新冠疫情导致癌症筛查大幅下降。然而,疫情导致美国筛查总体不足。与新冠疫情相关的癌症筛查延迟被认为是导致与疫情直接相关的额外死亡人数的原因。在新冠疫情期间,尤其是在疫情高峰期,前列腺活检和 PC 诊断率下降。

        此外,在疫情爆发之前,欧洲(主要是英国)的影像服务长期投资不足,缺乏影像采集和报告能力。例如,这与严重的劳动力和设备短缺有关。但随着新的 IPC 措施的实施,特别是所有医疗机构的 2 米社交距离,这些短缺已使 CT 容量在撰写本文时达到新冠疫情前水平的约 40-70%。此外,MRI 略好一些,占 80%。此外,影像服务正在努力通过恢复容量和恢复患者信心来重获动力。显然,只有通过大量投资来解决放射科医生、放射技师和影像设备的长期资金不足问题,才能实现根本性改变。  

         

        前列腺癌核医学诊断市场报告范围

        报告属性细节
        2022 年市场规模7.2012亿美元
        2028 年市场规模13.1566亿美元
        全球复合年增长率(2022 - 2028)10.6%
        历史数据2020-2021
        预测期2023-2028
        涵盖的领域按类型
        • PET 和 SPECT
        按 PET 产品
        • F-18
        • C-11
        • Ga68-PSMA
        按最终用户
        • 医院
        • 诊所
        • 其他的
        覆盖地区和国家北美
        • 我们
        • 加拿大
        • 墨西哥
        欧洲
        • 英国
        • 德国
        • 法国
        • 俄罗斯
        • 意大利
        • 欧洲其他地区
        亚太
        • 中国
        • 印度
        • 日本
        • 澳大利亚
        • 亚太其他地区
        南美洲和中美洲
        • 巴西
        • 阿根廷
        • 南美洲和中美洲其他地区
        中东和非洲
        • 南非
        • 沙特阿拉伯
        • 阿联酋
        • 中东和非洲其他地区
        市场领导者和主要公司简介
        •  
        • 蓝地球诊断有限公司
        • 想象公司
        • 欢庆放射药物公司
        • NCM-美国有限责任公司
        • ABX 先进生化化合物有限公司
        • Telix 制药有限公司
        • 诺华公司
        • 治疗学
        • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

         

         

        前列腺癌核医学诊断——市场细分

        全球前列腺癌核医学诊断市场根据类型、PET 产品、最终用户和地理位置进行分析。就类型而言,市场分为 PET 和 SPECT。根据 PET 产品,市场细分为 F-18、C-11 和 Ga68-PSMA。根据最终用户,市场细分为医院、诊所和其他。从地理位置上看,前列腺癌核医学诊断市场细分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。  

         

        公司简介

        • 蓝地球诊断有限公司      
        • 想象抗体     
        • 锔        
        • 欢庆放射药物公司        
        • NCM-美国有限责任公司         
        • ABX 先进生化化合物有限公司     
        • Telix 制药有限公司            
        • 诺华公司           
        • 诊疗学         
        • Lantheus 医学成像公司

        Prostate Cancer Nuclear Medicine Diagnostics Market Report Scope

        Report Attribute Details
        Market size in US$ 720.12 Million
        Market Size by US$ 1,315.66 Million
        Global CAGR 10.6%
        Historical Data 2020-2021
        Forecast period 2023-2028
        Segments Covered By 类型(PET 和 SPECT)
        By PET 产品(F-18、C-11 和 Ga68-PSMA)
        By 最终用户(医院、诊所和其他)
        Regions and Countries Covered 北美(美国、加拿大、墨西哥)
        • 北美(美国、加拿大、墨西哥)
        欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
        • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
        亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
        • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
        南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
        • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
        中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
        • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
        Market leaders and key company profiles
      • Blue Earth Diagnostics Limited
      • ImaginAB
      • Curium
      • Jubilant Radiopharma
      • NCM USA LLC
      • ABX Advanced Biochemical Compounds GmbH
      • Telix Pharmaceuticals Ltd
      • Novartis AG
      • Theragonostics
      • Report Coverage
        Report Coverage

        Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

        Segment Covered
        Segment Covered

        This text is related
        to segments covered.

        Regional Scope
        Regional Scope

        North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

        Country Scope
        Country Scope

        This text is related
        to country scope.

        Frequently Asked Questions


        Which region is dominating the prostate cancer nuclear medicine diagnostics market?

        The global prostate cancer nuclear medicine diagnostics market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. In 2021, North American region held largest market share. However, Asia Pacific region is estimated to grow at the fastest CAGR of 11.2% during the forecast period

        Which segment is dominating the prostate cancer nuclear medicine diagnostics market?

        The global prostate cancer nuclear medicine diagnostics market based on type, is segmented into SPECT and PET. In 2021, PET segment held largest market share and the segment is estimated to grow at the fastest CAGR of 10.8% during the forecast period.

        What are the restraining factors for the prostate cancer nuclear medicine diagnostics market across the country?

        The high cost related to the prostate cancer diagnostics and treatment is expected to restrict the market growth during the forecast period

        Who are the major players in market the prostate cancer nuclear medicine diagnostics market?

        The prostate cancer nuclear medicine diagnostics market majorly consists of the players such as Blue Earth Diagnostics Limited, ImaginAB, Curium, Jubilant Radiopharma, NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH, Telix Pharmaceuticals Ltd., Novartis AG, Theragonostics, and Lantheus Medical Imaging Inc.

        What are the driving factors for the prostate cancer nuclear medicine diagnostics market across the country?

        Factors such as the rising prevalence of prostate cancer and surging demand for early and precise diagnosis of prostate cancer.

        What is the prostate cancer nuclear medicine diagnostics market?

        Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Some common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. Prostate cancer (PCa) is the fourth most common cancer across the US in terms of occurrence.

        The List of Companies - Prostate Cancer Nuclear Medicine Diagnostics Market

        1. Blue Earth Diagnostics Limited
        2. ImaginAB
        3. Curium
        4. Jubilant Radiopharma
        5. NCM-USA LLC
        6. ABX Advanced Biochemical Compounds GmbH
        7. Telix Pharmaceuticals Ltd.
        8. Novartis AG
        9. Theragonostics
        10. Lantheus Medical Imaging Inc.

        The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

        1. Data Collection and Secondary Research:

        As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

        Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

        1. Primary Research:

        The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

        For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

        A typical research interview fulfils the following functions:

        • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
        • Validates and strengthens in-house secondary research findings
        • Develops the analysis team’s expertise and market understanding

        Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

        • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
        • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

        Below is the breakup of our primary respondents by company, designation, and region:

        Research Methodology

        Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

        1. Data Analysis:

        Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

        • Macro-Economic Factor Analysis:

        We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

        • Country Level Data:

        Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

        • Company Profile:

        The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

        • Developing Base Number:

        Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

        1. Data Triangulation and Final Review:

        The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

        We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

        We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

        Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

        Trends and growth analysis reports related to Pharmaceuticals : READ MORE..